Her-2 neu dna vaccine having anti-cancer activity

a plasmid and anti-cancer technology, which is applied in the field of human her2-neu expressing plasmid constructs with anti-cancer activity and a dna vaccine, can solve the problems of slow gain of anti-cancer immunity, overexpression of the encoded 185 kda receptor tyrosine kinase, and no successful therapeutic efficacy using only her-2/neu expressing plasmids, and achieves high anti-can

Inactive Publication Date: 2006-04-06
VIROMED CO LTD
View PDF1 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0008] Accordingly, it is an object of the present invention to provide a human Her-2 / neu expressing plasmid construct having high antitumor activity.

Problems solved by technology

Amplification of this gene results in overexpression of the encoded 185 kDa receptor tyrosine kinase.
Although successful preventive efficacy against Her-2 / neu expressing tumor by DNA vaccination was achieved by many earlier experiments, no successful therapeutic efficacy was reported using only Her-2 / neu expressing plasmids.
The difficulty lies on the slow gain of antitumor immunity due to the lag time before antigenic expression of Her-2 / neu expressing plasmids, while mammary tumor grows relatively fast.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Her-2 neu dna vaccine having anti-cancer activity
  • Her-2 neu dna vaccine having anti-cancer activity
  • Her-2 neu dna vaccine having anti-cancer activity

Examples

Experimental program
Comparison scheme
Effect test

reference example 1

Cell Lines and Animals

[0073] The Her-2 / neu expressing human breast carcinoma SK-BR3 cell line (ATCC HTB-30) and murine colon adenocarcinoma cell line CT26 (ATCC CRL-2639) were obtained from the American Type Culture Collection (Manassas, Va., USA). Human breast cancer cell line SK-BR3 cells were maintained in RPMI1640 (BioWhittaker, Walkersvile, Md.) supplemented with 10% heat-inactivated fetal bovine serum (FBS, GIBCO, Gaithersburg, Md.) and 1% penicillin-streptomycin (GIBCO). Her-2 / neu-expressing transfectoma Her2-CT26 cells were prepared by transduction of CT26 cells with the cDNA-encoding human Her-2 / neu (NCBI: M1730). Her2 / CT26 and CT26 cells were cultured in IMDM (BioWhittaker) containing 10% heat-inactivated FBS and 1% penicillin-streptomycin.

[0074] Female 5-week-old BALB / C mice were purchased from Charles River (Osaka, Japan) and kept at 22° C., 55% relative humidity, and a daily lighting cycle of 12 hrs light / 12 hrs dark with free access to food and water. The mice were h...

reference example 2

Isolation of DNA Plasmids for i.m. Injection

[0075]Escherichia coli strain DH5α transformed with each of the plasmids, pNeuTM, pNeuECD, pNeuTM-gDs, pNeuECD-gDs, pCKTM and pCKECD, control vectors pTV2 and pCK, was grown in LB broth (Difco, Detroit, Mich.). Large-scale preparation of the plasmid DNA was carried out by the alkaline lysis method using an Endofree Qiagen Plasmid-Giga kit (Qiagen, Chatsworth, Calif.) according to the manufacturer's instructions. DNA was then precipitated, suspended in sterile PBS (BioWhittaker) at a concentration of 2 mg / ml, and stored in aliquots at −20° C. for subsequent use in immunization protocols.

reference example 3

Flow Cytometry (FACS)

[0076] To examine whether sera could specifically react Her-2 / neu surface protein, SK-BR3, Her2-CT26 and CT26 cells were stripped from the culture flasks with a cell scraper (Nunc, Naperville, Ill.). Removed cells were washed in an FACS buffer consisting of RPMI1640 supplemented with 2% FBS and 0.1% sodium azide. Approximately 2×105 cells per analysis were incubated together with a serial dilute of a serum or control antibody at 4° C. for 30 min. Cells were washed 3 times a serial dilute of the same FACS buffer and then stained for 30 minutes at 4° C. with an FITC-conjugated goat monoclonal antibody specific for mouse IgG (Sigma). Stained cells were washed 2 times and resuspended in the same FACS buffer. To exclude dead cells from data, 1 μg / ml propidium iodide (Sigma) was added to the cell suspension and incubated for 30 sec prior to analysis. Only the cells that were negative by propidium iodide staining were gated and further analyzed for binding to tumor ce...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
timeaaaaaaaaaa
temperaturesaaaaaaaaaa
concentrationaaaaaaaaaa
Login to view more

Abstract

The present invention relates to human Her-2 / neu expressing plasmid constructs having anti-cancer activity and a DNA vaccine comprising same for preventing and / or treating cancer. The Her-2 / neu DNA vaccines of the present invention can be effectively used as a therapeutic vaccine in reducing metastasis after tumor surgery or as a prophylactic vaccine for people with genetic high risk.

Description

FIELD OF THE INVENTION [0001] The present invention relates to human Her-2 / neu expressing plasmid constructs having anti-cancer activity and a DNA vaccine comprising same for preventing and treating cancer. BACKGROUND OF THE INVENTION [0002] The Her-2 / neu or erbB-2 gene encodes a transmembrane protein that is a member of the type I family of growth factor receptors (Akiyama, T. et al., Science 232: 1644-1646, 1986). Amplification of this gene results in overexpression of the encoded 185 kDa receptor tyrosine kinase. [0003] The Her-2 / neu protein has been found to be amplified and overexpressed in several types of human adenocarcinomas, especially in tumors of the breast and the ovary. The overexpression was correlated with short relapse time and poor survival rate of breast cancer patients (Slamon, D. J. et al., Science 235: 177-182, 1987), suggesting that Her-2 / neu overexpression likely plays a critical role in the development of human cancers. Several lines of evidence also support...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K48/00A61K31/711A61K38/00A61K39/00A61K45/00A61P35/00C12N15/85
CPCA61K39/0011A61K2039/53A61K2039/55522C07K2319/02C12N2840/203A61P35/00A61K39/001106C12N15/85
Inventor LEE, JOONKIM, DONG-HYEONCHUNG, YEONSEOKCHANG, SUN-YOUNGLEE, KYUNG-CHULKANG, CHANG-YUIL
Owner VIROMED CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap